1.37
-0.07(-4.86%)
Currency In USD
Address
2001 Market Street
Philadelphia, PA 19103
United States of America
Phone
267 225 7416
Sector
Healthcare
Industry
Biotechnology
Employees
12
First IPO Date
October 20, 2021
| Name | Title | Pay | Year Born |
| Mr. Martin A. Lehr | Co-Founder, President, Chief Executive Officer & Director | 765,596 | 1984 |
| Dr. Karen L. Smith L.L.M., M.B.A., M.D., PH.D. | Interim Chief Medical Officer & Director | 14,552 | 1968 |
| Mr. Alex C. Levit Esq., J.D. | Chief Legal Officer & Corporate Secretary | 541,334 | 1979 |
| Ms. Jennifer Minai-Azary | Chief Financial Officer & Treasurer | 564,090 | 1978 |
| Mr. Christopher Beck M.B.A. | Senior Vice President of Operations | 0 | N/A |
| Ms. Jennifer Dashnau M.B.A., Ph.D. | Senior Vice President of Technical Operations | 0 | N/A |
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.